Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis

Published:2017-05 Issue: Volume:79 Page:4-16
ISSN:0896-8411
Container-title:Journal of Autoimmunity
language:en
Short-container-title:Journal of Autoimmunity

Author:

Komaki Yuga,Yamada Akihiro^ORCID,Komaki Fukiko,Kudaravalli Praneeth,Micic Dejan,Ido Akio,Sakuraba Atsushi^ORCID

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference50 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution;Kuek;Postgrad. Med. J.,2007

3. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues;Use CfMPfH,2014

4. Information for Consumers (Biosimilars);Food,2015

5. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs);Organization WH,2009

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

2. Rheumatology: What You May Have Missed in 2023;Annals of Internal Medicine;2024-05

3. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID;Therapeutic Advances in Gastroenterology;2024-01

4. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis;JAMA Network Open;2023-05-26

5. Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis;BioDrugs;2023-03-23